---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-040742"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:15:37.898260+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phase 2 interim data: 100% tumor control, 88% vision preservation with bel-sar in early choroidal melanoma

## Summary
- 100% tumor control (8/8) and 88% visual acuity preservation in patients receiving three cycles of bel-sar.
- Statistically significant reduction in tumor growth rate: -0.289 mm/yr (p<0.0001) vs. each patient's documented rate.
- No treatment-related SAEs; only mild anterior inflammation (Grade 1) in 20% of patients.
- Company plans to initiate global Phase 3 trial enrollment this year based on these data.
- Data presented at Macula Society 46th Annual Meeting with average 9 months follow-up.

## SEC filing metadata
- accession: 0001193125-23-040742
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312523040742/0001193125-23-040742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312523040742/d460344d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-040742
- JSON: https://secwatch.observer/filing/0001193125-23-040742.json
- Plain text: https://secwatch.observer/filing/0001193125-23-040742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.